C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy

Wang, Yingbing; Rapalino, Otto; Heidari, Pedram; Loeffler, Jay S.; Shih, Helen A.; Oh, Kevin; Mahmood, Umar

doi:10.1016/j.ijrobp.2018.06.011

Cited by 19 publications

(15 citation statements)

References 9 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It would be interesting to note if MGMT methylation was associated with MTV response as it has been associated with change in standardized uptake. 46…”

Section: Discussionmentioning

confidence: 99%

Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone

Miller

Schipper

et al. 2020

Advances in Radiation Oncology

View full text Add to dashboard Cite

To evaluate whether response assessment of newly diagnosed glioblastoma at 3 months using 11 C-methionine-positron emission tomography (MET-PET) is better associated with patient outcome compared with baseline MET-PET or anatomic magnetic resonance imaging alone. Methods and Materials: Patients included were participants in a phase I/II trial of dose-escalated chemoradiation based on anatomic magnetic resonance imaging. Automated segmentation of metabolic tumor volume (MTV) was performed at a threshold of 1.5 times mean cerebellar uptake. Progression-free (PFS) and overall survival were estimated with the Kaplan-Meier method and compared with log-rank tests. Multivariate analysis for PFS and overall survival was performed using Cox proportional hazards, and spatial overlap between imaging and recurrence volumes were analyzed. Results: Among 37 patients, 15 had gross total resection, of whom 10 (67%) had residual MTV, 16 subtotal resection, and 6 biopsy alone. Median radiation therapy dose was 75 Gy (range, 66-81). Median baseline T1 Gd-enhanced tumor volume (GTV-Gd) was 38.0 cm 3 (range, 8.0-81.5). Median pre-CRT MTV was 4.9 cm 3 (range, 0-43.8). Among 25 patients with 3-month MET-PET, MTV was only 2.4 cm 3 (range, 0.004-18.0) in patients with uptake. Patients with MTV Z 0 cm 3 at 3 months had superior PFS (18.2 vs 10.1 months,

show abstract

“…It would be interesting to note if MGMT methylation was associated with MTV response as it has been associated with change in standardized uptake. 46…”

Section: Discussionmentioning

confidence: 99%

Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone

Miller

Schipper

et al. 2020

Advances in Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…In contrast to [ 18 F]FDG, which is not valuable for the response prediction to radiotherapy [23,24], early [ 18 F]FETor [ 11 C]MET-PET changes are predictors for progressionfree survival (PFS) and overall survival (OS) [25][26][27][28][29].…”

Section: Treatment Response and Radiation-induced Changesmentioning

confidence: 99%

Value of PET imaging for radiation therapy

et al. 2021

View full text Add to dashboard Cite

This comprehensive review written by experts in their field gives an overview on the current status of incorporating positron emission tomography (PET) into radiation treatment planning. Moreover, it highlights ongoing studies for treatment individualisation and per-treatment tumour response monitoring for various primary tumours. Novel tracers and image analysis methods are discussed. The authors believe this contribution to be of crucial value for experts in the field as well as for policy makers deciding on the reimbursement of this powerful imaging modality.

show abstract

“…11 C-Met is an excellently sensitive method by which we can obtain a substantial amount of information on protein synthesis. Moreover, it has often been applied for delineating tumor margins, detecting tumors, and differentiating various cancers from reactive changes [32][33][34]. In 2009, Nariai and colleagues examined a comparative study of 18 FBPA and 11 C-Met PET in 12 patients with malignant glioma and found that the T/N ratios of 18 FBPA and 11 C-Met showed significant linear correlations.…”

Section: Imaging Techniques Other Than 18 Fbpa Petmentioning

confidence: 99%

Development of an Imaging Technique for Boron Neutron Capture Therapy

Fukumitsu¹,

Matsumoto

2021

Cells

View full text Add to dashboard Cite

The development of 4-10B-borono-2-18F-fluoro-L-phenylalanine (18FBPA) for use in positron emission tomography (PET) has contributed to the progress of boron neutron capture therapy (BNCT). 18FBPA has shown similar pharmacokinetics and distribution to 4-10B-borono-L-phenylalanine (BPA) under various conditions in many animal studies. 18FBPA PET is useful for treatment indication. A higher 18FBPA accumulation ratio of the tumor to the surrounding normal tissue (T/N ratio) indicates that a superior treatment effect is expected. In clinical settings, a T/N ratio of higher than 2.5 or 3 is often used for patient selection. Moreover, 18FBPA PET is useful for predicting the 10B concentration delivered to the tumor and surrounding normal tissues, enabling high-precision treatment planning. Precise dose prediction using 18FBPA PET data has greatly improved the treatment accuracy of BNCT. However, the methodology used for the data analysis of 18FBPA PET findings varies; thus, data should be evaluated using a consistent methodology so as to be more reliable. In addition to PET applications, the development of 18FBPA as a contrast agent for magnetic resonance imaging that combines gadolinium and 10B is also in progress.

show abstract

C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy

Cited by 19 publications

References 9 publications

Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone

Metabolic Tumor Volume Response Assessment Using (11)C-Methionine Positron Emission Tomography Identifies Glioblastoma Tumor Subregions That Predict Progression Better Than Baseline or Anatomic Magnetic Resonance Imaging Alone

Value of PET imaging for radiation therapy

Development of an Imaging Technique for Boron Neutron Capture Therapy

Contact Info

Product

Resources

About